Efficacy of neoadjuvant immunochemotherapy in the treatment of stage III non-small-cell lung cancer with cancer driver gene mutations
The potential of neoadjuvant immunochemotherapy for patients with stage III NSCLC with cancer driver gene mutations is promising.
Authors
- Linhai Zhu (ORCID: https://orcid.org/0000-0002-0433-5348)
- Yuhong Yang (ORCID: https://orcid.org/0000-0003-3618-3083)
- Nagashree Seetharamu (ORCID: https://orcid.org/0000-0002-3282-7622)
- Jinming Xu
- Wang Lv (ORCID: https://orcid.org/0009-0007-2014-0480)
- Hiroyuki Adachi (ORCID: https://orcid.org/0000-0002-8928-9394)
- Pinghui Xia
- Jiayue Ye (ORCID: https://orcid.org/0000-0002-0371-0660)
- Chong Zhang (ORCID: https://orcid.org/0000-0002-5014-4331)
- Xuhua Huang (ORCID: https://orcid.org/0000-0002-0022-2661)
- Yiqing Wang (ORCID: https://orcid.org/0000-0002-5626-8589)
- Jia-Cong Liu
Institutions
- Northwell Health (US)
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
- Yokohama City University (JP)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/tlcr-2025-60
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52